and multiple myeloma wherein MYD88 L265P was either absent or infrequently observed (<10%). 4, 5, 6 Importantly, MYD88 L265P was present in IgM MGUS with a frequency of 50-80% using allele specific (AS) polymerase chain reaction (PCR) suggesting an early oncogenic event for this mutation, and that other genomic events are likely to be responsible for WM disease progression.
Activating MYD88 mutations are not unique to WM and appear in other B-cell lymphomas including primary central nervous system lymphoma (50%), and activated B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL) (8%-29%). 7, 8, 9 A multi-hit model would also help explain why no significant differences in treatment response, progression free and overall survival based solely on MYD88 mutation status determination were observed in a large series of WM patients. 10 Little is known about genetic structural variant (SV) changes such as copy number alterations (CNA) or translocations in WM. By fluorescence in situ
For personal use only. at UNIV OF PITTSBURGH HSLS on January 3, 2014. bloodjournal.hematologylibrary.org From hybridization (FISH) and array comparative genomic hybridization (aCGH) deletions in chromosome 6q21-23 have been identified in 40%-60% of WM patients, with concordant gains in 6p in 41% of those with 6q deletions. [11] [12] [13] Gains in chromosomes 3q, 4, 18, 8q and Xq as well as losses of 11q23, 13q14, and 17p have also been described in up to 20% of WM cases.
14, 15 We therefore sought to more fully characterize the molecular events responsible for WM pathogenesis using WGS.
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METHODS

Sample Collection and Preparation
Bone marrow aspirates and peripheral blood (PB) samples were collected in heparinized syringes from thirty patients with the clinicopathological diagnosis of WM as defined by the Second International Workshop on WM. 16 Participants provided informed consent prior to sample collection in accordance with the 
RESULTS
Thirty patients meeting the International Consensus Criteria for WM diagnosis were evaluated in this study. 16 The clinical characteristics were typical of WM of this cohort are presented in Supplemental Table S2 ). Genes were further categorized by mutational frequency and validated based on bioinformatic strength and biological relevance, using Sanger sequencing of both tumor and germline DNA (Table 1) .
These cut off scores were significantly lower than our previous analysis allowing for the detection of a number of additional mutations. Primers and representative chromatograms are provided in Supplementary Table S3 . A full list of somatic, and germline mutations affecting genes in the COSMIC cancer gene census are shown in Supplementary Tables S4 and S5, respectively.
17
As previously described, a somatic T/C mutation in MYD88 resulting in an L265P
substitution was observed in 27/30 samples. In addition to the L/P activating substitution in the primary transcript, this mutation results in a stop loss in two of
For personal use only. at UNIV OF PITTSBURGH HSLS on January 3, 2014. bloodjournal.hematologylibrary.org From the alternative isoforms. The potential functional significance for these shorter transcripts in MYD88 L265P is not known. A subclonal C/G mutation was found in MYD88 resulting in an amino acid substitution (S219C) in one patient who also had the L265P mutation. 8 No other mutations in MYD88 were observed in the study population.
To better understand the MYD88 wild type (WT) population, we identified somatic mutations found exclusively in the 3 MYD88 WT patients. Cross listing these genes with COSMIC, we observed that 2 of these 3 (67%) patients had damaging mutations in MLL2 while mutations in the genes JAK2, PRCC, SUZ12, BCL10, KDM6A, and SETD2 were each observed once. Sanger sequencing confirmed the somatic presence of MLL2 mutations in these patients as previously described. 4 While a larger sample size is needed to determine if the high frequency of MLL2 mutations is typical of the MYD88 WT WM population, it nonetheless represents a gene of great interest since MLL2 mutations are highly recurrent in follicular lymphoma and DLBCL patients. 18 The next most common somatic mutation was observed in the G-protein coupled receptor (GPCR) CXCR4. CXCR4 is a chemokine receptor that promotes WM survival, migration, and adhesion to the bone marrow (BM) stroma through interactions with its ligand CXCL12. 19 Other genes with validated somatic mutations in this series included ARID1A 
Structural Variant Analysis
Structural variants were inferred from high confidence discordant mate-pair and relative coverage data supplied by Complete Genomics. To gain further insight into the SV events underling WM, we combined individual patient data for lesser allele fraction (LAF), heterozygous call rate, normalized relative coverage, somatic CNAs, and somatic SV calculations with cohort wide small variant distribution and CNA regions of statistical significance (Supplementary Figure   S1 ). These analyses aid in the detection of complex events such as acquired uniparental disomies (aUPD), which can be observed in chromosomes 3p and 21 in Supplementary Figure S1 . The most common aUPD was at 3p, occurring in 4/30 (13%) of patients and whose location and size were highly conserved between the samples ( Figure 3 ). This locus included the MYD88 L265P locus, resulting in homozygous somatic mutation in these patients. Additional large aUPDs were observed on chromosomes 1, 2, 5, 9, 17, 21, and X with many of these affecting the validated small variant findings (Table 2 ).
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One patient had two distinct t(2;17) translocations disrupting both alleles of RNF213. A t(6;X) translocation disrupting the gene BIA3 was responsible for the chromosome 6q deletion observed in another patient (Supplementary Figure S1) .
A third patient had a chromothriptic event centered on chromosome 6 which made up over half of all translocations observed in this study (Supplementary Figure S2) , and contributed to 6q deletions observed in this patient's tumor cells.
In this patient, we performed PCR for t(6;7) predicted to disrupt BMP5 and ANKRD7, as well as t(6;11) predicted to disrupt GRIA4 and PKHD1 respectively, and validated both of these findings. 
14,15
Small Somatic Copy Number Alterations
To detect small somatic deletions and amplifications, we calculated 100Kb blocks of the log-transformed ratio of tumor to germline relative coverage in each of the paired genomes. Significant CNAs were then compared across all 10 patients in order to identify statistically significant regions. CNAs consisted mostly of isolated 100Kb blocks both within and outside of chromosome 6 (Supplementary Table   S6 and Supplementary Figure S1E) . To investigate the biological relevance of these non-chromosome 6 CNAs, we performed functional enrichment analysis on the gene set affected by these alterations. Unique functional annotation results are listed in order of significance in Figure 4A .
For personal use only. at UNIV OF PITTSBURGH HSLS on January 3, 2014. bloodjournal.hematologylibrary.org From To better characterize these highly recurrent deletions, consecutive blocks of equal significance were merged together to form 194 statistically significant regions with a median length 100Kb (range 100Kb-4,900Kb). Of these regions, 134 (69%) were found outside of chromosome 6 with a median length of 100Kb (range 100Kb-300Kb), of which 126 of 134 (94%) were restricted to a single 100Kb region. Within chromosome 6, CNAs were larger with only 30/60 (50%) CNAs constituting single 100Kb regions (p=7.709x10 -12 ). CNAs targeted COSMIC census genes for 14 of 172 (8.14%) genes outside of chromosome 6, versus 4 of 239 (1.67%) genes within chromosome 6 respectively (p=0.0024). To determine the probability of generating these results as a random by-product of genomic instability, we calculated the number of total genes affected by these deletions (N=411) and the number of these genes found in the COSMIC database (N=18). We randomly distributed matching deletion sets across the genome and enumerated the total number of overlapping genes and the number of those genes listed in the COSMIC census ( Figure 4B ). These simulations revealed a statistically significant increase in targeting of COSMIC genes by CNAs outside of chromosome 6. Affected genes in the COSMIC census were BTG1 (9/10; 90%), FOXP1 (7/10; 70%), FNBP1 (7/10; 70%), CD74 (7/10; 70%), TOP1 (6/10; 60%), MYB (5/10; 50%), CBLB (5/10; 50%), ETV6 (5/10; 50%), TNFAIP3 (5/10; 50%), FBXW7 (5/10; 50%), PRDM1 (5/10; 50%), TFE3 (4/10; 40%), JAK1 (4/10; 40%), MAML2 (4/10; 40%), FAM46C (4/10; 40%), EBF1 (4/10; 40%), STL (4/10; 40%), and BIRC3 (4/10; 40%). Other affected genes of interested included PRDM2 (8/10; 80%), HIVEP2 (8/10; 80%), ARID1B (7/10; 70%) as well as LYN (7/10; 70%).
There were no singular regions of statistical significance in 6q. Some patients had multifocal deletions in this region suggesting multiple target genes ( Figure 5 ).
Neither of the previously suspected target genes for 6q loss, i.e. PRDM1 and TNFAIP3 were included in the regions of highest statistical significance. 11, 12 The relative coverage data from all 10-paired patients is shown in Figure 6b For personal use only. at UNIV OF PITTSBURGH HSLS on January 3, 2014. bloodjournal.hematologylibrary.org From illustrating that only 3 patients had highly clonal deletions in 6q. Two additional patients had subclonal deletions in 6q, therefore 5/10 (50%) paired patients had at least subclonal loss. Deletions in HIVEP2 (8/10; 80%) as well as ARID1B (7/10; 70%) and BCLAF1 (7/10; 70%) constituted the most common deletions in chromosome 6, and were present in patients with and without visible 6q losses.
To test our validation system and examine the accuracy of the GC normalized relative coverage data, we used a PCR based copy number assay to validate the established 6q22 deletion in a subset of patients ( Figure 6A ). Having recapitulated the expected results, we conducted additional validation studies for eight of our top targets in the same five patients using commercially available assays. While many results appeared subclonal, we observed a strong correlation between the PCR relative copy number and WGS coverage predictions ( Figure 6D ). To establish the frequency of these CNAs, we validated these eight findings in an independent cohort of 30 WM patients revealing There were fewer median validated deletions in CXCR4 mutated patients (5) compared to WT (7; p=0.002) and with the median total number of 6q CNAs (2) compared to WT (3; p=0.007; Figure 2 ). This was also true for any combination of two of the three validated 6q genes ruling out possible biasing by a single gene (p<0.023 for all).
For
DISCUSSION
The most pronounced finding from this work was the discovery of a somatic mutation in MYD88 (L265P), which was present in 90% of patients with WM. The details for this discovery were previously published following the preliminary examination of our whole genome sequencing results. 4 MYD88 serves as an adaptor molecule in Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R)
signaling mediating IRAK4 and IRAK1 activation and down stream signaling through NFKB. 4, 8, 26 Mutations in MYD88 are significant given the importance of NFκB signaling in WM cell growth and survival. 27 We recently demonstrated that MYD88 L265P can trigger NFκB signaling through an IRAK-independent pathway by direct interaction with Bruton's Tyrosine Kinase (BTK) in WM cells, suggesting parallel pathways for NFκB activation. 28 In contrast to the findings by Ngo et al who observed multiple MYD88 mutations (L265P, V217F, S219C, M232T, S243N, T294P) in ABC subtyped DLBCL patients, our findings were limited to the identification of L265P, and S219C as a subclonal event in one WM patient with a L265P mutation. 8 We also did not observe mutations in CARD11 in WM patients, demonstrating differences in potential oncogenic drivers and dependence on TLR signaling for WM versus ABC subtyped DLBCL.
The next most common somatic variant after MYD88 L265P was in CXCR4, present in 27% of the patients. The mutations identified in WM tumor cells recapitulated those found in the germline of patients with WHIM syndrome. To our knowledge, this is the first time WHIM like mutations have ever appeared as somatic mutations, and also associated with a malignant disease. In WHIM syndrome, loss of regulatory serines in the c-tail of CXCR4 are known to impair receptor internalization, thereby prolonging G-protein and β -arrestin signaling.
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CXCR4 stimulation by its ligand CXCL12 is known to activate AKT1 and MAPK family signaling, as well as facilitate cell migration and homing in WM cells. 19 The prolonged activation of CXCR4 signaling due to WHIM mutations may therefore exaggerate these effects in WM cells, and deserves further study. Nearly all For personal use only. at UNIV OF PITTSBURGH HSLS on January 3, 2014. bloodjournal.hematologylibrary.org From patients with CXCR4 mutations also had carried the MYD88 L265P mutation, and comprehensive studies will be required to delineate the relative impact of these mutations on WM clinical and treatment response characteristics. The presence of CXCR4 mutations may also offer a targeted approach to therapy of WM by use of CXCR4 antagonists given their successful employment in the treatment of WHIM syndrome patients. 29 Several antagonists to CXCR4 have been developed and are in clinical trials including plerixafor, BMS-936564, AMD-070, TG-0054 and others and warrant investigation alone and/or in combination in WM patients.
While most WM cases in our series did not have mutations in CXCR4, it is possible that CXCR4 signaling may still be critical for many of these patients and offer an opportunity for targeted therapy with CXCR4 antagonists. 21 In WM, polymorphisms of the CXCR4 ligand, CXCL12, have been associated with poor post treatment clinical outcomes. 30 Copy loss of RGS17 that was observed in 5 of 10 (50%) of patients in our series may also affect this pathway. CXCR4 signals downstream through G iα G-proteins increasing phosphorylated AKT1 levels and promoting cell survival while RGS17 inhibits G iα G-proteins by promoting GTP hydrolysis. 31, 32 In an analogous case, RGS17 inactivation was observed in ovarian cancer affecting G iα GPCR downstream signaling in response to lysophosphatidic acid. 31 The other major pathway identified in this study was the loss of the chromatin remodeling proteins, ARID1A and ARID1B. 33 ARID1A was the third most common SNV variant target in WM, with 5/30 (17%) of patients having validated nonsense or frame shift mutations. In one patient, a mutation in ARID1A (Y551 frameshift) was homozygous as a result of an aUPD, whereas in another patient a nonsense mutation (Q2037*) was opposite CNA loss resulting in biallelic inactivation ( Table 2) . Loss of the alternate family member ARID1B was present in 7/10 (70%) of the paired patient samples making it a more frequent 6q target than either PRDM1 or TNFAIP3 (5/10; 50% for both). 33 One potential target for For personal use only. at UNIV OF PITTSBURGH HSLS on January 3, 2014. bloodjournal.hematologylibrary.org From in our study and suggests that these events may be functionally related. 52 Preclinical studies of BTG1 in ALL have shown that loss of BTG1 is associated with glucocorticoid resistance. These findings may explain the poor responses observed to single agent steroids in WM, and warrant further investigation of BTG1 loss in treatment outcomes in patients undergoing glucocorticoid inclusive therapy. 53, 54 Finally, biallelic loss of RNF213 resulting from two distinct t(2;17)s was observed in 1 of 10 paired patients, and represents an interesting finding since RNF213 is a fusion partner of ALK and MYC in acute anaplastic large cell lymphoma. In the WM patient with the t(2;17) translocation, RNF213 was translocated to the intergenic space indicating that the loss of RNF213 itself may play an important role in oncogenesis. 55, 56 It is important to note that most CNAs were consistent with heterozygous loss and classical tumor suppressors require biallelic loss for oncogenesis. However, these losses could lead to pathway modulation due to altered protein levels or creation of dominant negatives by partial gene loss. For personal use only. at UNIV OF PITTSBURGH HSLS on January 3, 2014. bloodjournal.hematologylibrary.org From
The loss in 7/10 (70%; 18/30 in validation) paired patients of LYN, a kinase that plays a regulatory role for B-cell receptor (BCR) signaling along with mutations in CD79B (2/30; 7%) indicates a possible role for BCR signaling in this disease. [60] [61] [62] The loss of IBTK in 4/10 (40%) of patients, and the interaction between activated MYD88 and BTK, raises the possibility for BTK mediated cross-talk with the TLR/MYD88 pathway wherein BTK plays an important role in NFκB activation. 28, [63] [64] [65] Moreover, CBLB, a gene disrupted in chronic myelogenous leukemia and lost in 5/10 (50%) of the paired patients has been shown to inhibit the TLR4 response during inflammation by controlling TRL4 and MYD88 association, and subsequent NFκB activation. 66, 67 However, there is still limited data regarding the structure of the MYD88 L265P mutant protein. Signaling pathways that are well documented in the wild type setting will need to be carefully re-examined to clarify the contribution of the L265P mutation to downstream MYD88 signaling.
Our WGS studies in WM patients have therefore identified mutations in genes involving TLR, NFκB, and CXCR4 signaling, chromatin remodeling, and cell cycle regulation. These findings may denote a multistep process for WM evolution from IgM MGUS to asymptomatic and symptomatic WM, which invariably will require comparative, and even prospective longitudinal sequencing studies. These efforts are particularly warranted since the principal mutation (MYD88 L265P) identified in these studies is also present in 50-80% of IgM MGUS patients using AS-PCR, signifying its role as an early oncogenic event. 10, 68, 69 Other mutations therefore are likely to be acquired in the evolution of MGUS to symptomatic WM, and may offer opportunity to identify those patients at high risk for disease evolution. Lastly, these studies have also identified novel targets for rationale approach to WM treatment, including potentially the use of inhibitors targeting TLR and CXCR4 signaling. 
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